bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s Why
by Scott Moore · The Cerbat GembioMerieux (OTCMKTS:BMXMF – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $105.41, but opened at $84.29. bioMerieux shares last traded at $84.29, with a volume of 200 shares.
Analyst Ratings Changes
A number of research firms recently issued reports on BMXMF. Deutsche Bank Aktiengesellschaft downgraded shares of bioMerieux from a “buy” rating to a “hold” rating in a report on Friday. BNP Paribas Exane downgraded shares of bioMerieux to a “neutral” rating in a research report on Wednesday, January 28th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold”.
Get Our Latest Stock Report on BMXMF
bioMerieux Stock Performance
The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The business has a 50-day moving average price of $109.28 and a 200 day moving average price of $119.03.
bioMerieux Company Profile
bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.